ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.
about
Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective TherapyCost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphomaMantle cell lymphoma concurrent with T-large granular lymphocytic leukemia: report of a case and review of literatureThe EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphomaClinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter studyCarboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphomaBarriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 studyCombined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphomaLymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network.Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor responseBendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice.Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma.Clinical Outcome of Eradication Therapy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according to H. pylori Infection Status.Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue LymphomaEfficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphomaRole of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomasFDG-PET imaging in hematological malignanciesCorrelation of Endoscopic Findings of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma with Recurrence after Complete Remission.Current state of art for transplantation paradigms in peripheral T-cell lymphomas.Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.Current regimens and novel agents for mantle cell lymphoma.The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis.Profile of pacritinib and its potential in the treatment of hematologic disorders.Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.Flow cytometry immunophenotyping in integrated diagnostics of patients with newly diagnosed cytopenia: one tube 10-color 14-antibody screening panel and 3-tube extensive panel for detection of MDS-related features.Treatment options for mantle cell lymphoma.Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative.Bone marrow involvement is not associated with the clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma.The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models.Antiviral therapies for managing viral hepatitis in lymphoma patients.Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?Treatment approaches of hard-to-treat non-Hodgkin lymphomas.How to manage mantle cell lymphoma.
P2860
Q26750997-4ECEA62A-CAE7-4076-9763-91A490B7CCA4Q26770344-B5222C2B-DDE7-4B0C-A1BA-6A924EEEED45Q26779612-24051D5B-539A-4E26-8EDE-CB5C4A5D7BDDQ26994777-E01B0A7A-C3B8-4163-8481-EBEBA586670BQ27852536-5C143331-D718-4736-AF8F-66293089D196Q28080160-E32F74EC-0CA4-4445-BA63-D7C7EAD3474CQ31092020-66F2E66B-C2E7-4EDD-A462-3391D7BAA048Q33413598-933E4F99-404C-405C-AD1C-F5667EB04409Q33434137-073337FE-D820-442A-85B3-B853FEAE5CA8Q33440659-34C1CA75-29FC-4D81-B44E-0F096613A95AQ33587826-B6B0641E-FDED-4DDA-A402-F845E472A0D8Q33673144-17FD0CC9-950C-4412-9C25-0030550A9831Q33816002-62240D42-10F8-42AF-B844-AFA5192C1680Q35550255-60F1BF2A-9F2C-453C-89B8-D555C2870FC9Q35677959-7525AB60-7BF0-4DA9-B202-B6CAF23A25FBQ35741605-E90615C6-2C82-4B99-9E53-1FF1D0D95728Q35917095-8C893210-CBEA-4691-847C-1405A0EBC647Q36452240-8C913CC2-E06B-4415-B8B9-709D63E15AF2Q36681114-27AAC045-E0DB-42FB-AE12-763EB69F5C71Q37213503-12674384-304B-4778-A934-237A22D01AC9Q37544340-4CAF9DCC-86D4-40AC-B27D-BB6C36FEC728Q37578581-46846BA8-DBED-4329-8FC7-94D213218C68Q37632114-1A937BA3-B96B-43B7-9F2D-2569F8B34720Q37633931-A21D726E-EA36-4C74-BDB3-998135DC7390Q38132821-E2BB5989-EB5E-4BE2-ACB6-997C7C72A6C0Q38152510-FBA8E086-19ED-4727-A025-02A1412E2E54Q38224186-2C04B95C-C363-456D-B2C8-B6CE70EF75FDQ38230693-0F882805-931D-4689-ABCB-07F075691D82Q38232257-AAA95269-ADF3-492F-8BE1-694D635C9C76Q38244524-79D725E5-13E1-4412-B049-EE6D02A96EC2Q38387292-96F77568-7531-47DE-BC50-175AC5C4B334Q38482013-5238BDEB-B271-4D60-AD00-B32F670D65C0Q38584922-DFCCBE8D-0484-4E09-BD9D-BB802210C0AAQ38777496-FC5216C8-84EA-41EC-A58F-91D7AC634175Q38826502-688DAF14-9128-426E-B88B-E14473976890Q38847105-3AF04216-890F-4DE7-AAF1-B6ABE6820F46Q38989625-FC610E8C-AABA-41E0-9F64-4D87D92D3F69Q39044162-A220C002-9BED-4DA6-A07D-3267D4E0667FQ39091822-2C26E31D-44D0-4F8C-9411-CA2B0C18BE1BQ39187610-638073C1-8105-49C7-A8A6-3A8051F1E8B1
P2860
ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
ESMO Consensus conferences: gu ...... a, peripheral T-cell lymphoma.
@en
ESMO Consensus conferences: gu ...... a, peripheral T-cell lymphoma.
@nl
type
label
ESMO Consensus conferences: gu ...... a, peripheral T-cell lymphoma.
@en
ESMO Consensus conferences: gu ...... a, peripheral T-cell lymphoma.
@nl
prefLabel
ESMO Consensus conferences: gu ...... a, peripheral T-cell lymphoma.
@en
ESMO Consensus conferences: gu ...... a, peripheral T-cell lymphoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
ESMO Consensus conferences: gu ...... ma, peripheral T-cell lymphoma
@en
P2093
A Gallamini
A Wotherspoon
C Thieblemont
E Iannitto
J Rodriguez
M Dreyling
S Le Gouill
P2860
P304
P356
10.1093/ANNONC/MDS643
P50
P577
2013-02-20T00:00:00Z